Akebia Therapeutics, Inc. (AKBA)
Nasdaq · Healthcare · Drug Manufacturers - Specialty & Generic
$0.9105+5.26%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $252M
- 52-week range
- $0.814 – $3.20
- 52-week change
- −70.88%
- EPS (trailing)
- −$0.13
- Next earnings
- Nov 9, 2026
Fiscal year to Dec 2025
- Revenue
- $236M (+47.46%)
- Net income
- −$5.3M
- Operating margin
- 9.9%
- Diluted EPS
- −$0.02
- Free cash flow
- $67.7M
From the company’s annual report on SEC EDGAR.
About Akebia Therapeutics, Inc.
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD. The company is also developing AKB-9090, which is in Phase 2 clinical trial for treating cardiac surgery-related acute kidney injury and acute respiratory distress syndrome; and AKB-10108 for the treatment of retinopathy of prematurity in neonates.
Headquarters: Waltham, United States · 194 employees · akebia.com